PL EN


Preferences help
enabled [disable] Abstract
Number of results
2005 | 52 | 4 | 927-930
Article title

Modulation of ERK1/2 activity is crucial for sphingosine-induced death of glioma C6 cells

Content
Title variants
Languages of publication
EN
Abstracts
EN
In this study the contribution of the ERK1/2 pathway to sphingosine-induced death and morphological changes of the actin cytoskeleton in glioma C6 cells was investigated. Surprisingly, the level of ERK1/2 phosphorylation does not change after incubation of cells with sphingosine. Despite this, sphingosine induces rounding and detachment of cells without formation of apoptotic bodies. To shed light on this process, a specific inhibitor of ERK1/2 phosphorylation, U0126, was used. Cells incubated simultaneously with sphingosine and U0126 not only detached, but also exhibited formation of apoptotic-like blebs. These data suggest that during sphingosine-induced glioma C6 cell death apoptotic blebbing is dependent on ERK1/2 signalling and occurs only when ERK1/2 activity is decreased or abolished.
Publisher

Year
Volume
52
Issue
4
Pages
927-930
Physical description
Dates
published
2005
received
2005-07-07
revised
2005-10-19
accepted
2005-10-20
(unknown)
2005-11-21
Contributors
  • Laboratory of Signal Transduction, Department of Cellular and Molecular Neurobiology, Nencki Institute of Experimental Biology, Warszawa, Poland
References
  • Amran D (2005) Biochim Biophys Acta 1743: 269-279.
  • Bhaskara VK, Panigrahi M, Challa S, Babu PP (2005) Neuropathology 25: 48-53.
  • Boldt S, Weidle UH, Kolch W (2002) Carcinogenesis 23: 1831-1838.
  • Burstein E, Duckett CS (2003) Curr Opin Cell Biol 15: 732-737.
  • Chang SE, Kim KJ, Ro KH, Lim YJ, Choi JH, Moon KC, Sung KJ (2004) J Dermatol 31: 1-5.
  • Cuvillier O (2002) Biochim Biophys Acta 1585: 153-162.
  • Daido S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y, Kondo S (2004) Cancer Res 64: 4286-4293.
  • Dawson G, Goswami R, Kilkus J, Wiesner D, Dawson S (1998) Acta Biochim Polon 45: 287-297.
  • Domnina LV, Ivanova OY, Pletjushkina OY, Fetisova EK, Chernyak B, Skulachev VP, Vasiliev JM (2004) Cell Biol Int 28: 471-475.
  • Engelbrecht AM, Gebhardt S, Louw L (2005) Cancer Lett (available on line May 31).
  • Fang JY, Richardson BC (2005) Lancet Oncol 6: 322-327.
  • Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM (1998) J Biol Chem 273: 18623-18632.
  • Freeman SM (2004) Drug News Perspect 17: 237-242.
  • Green DR (1998) Cell 94: 695-698.
  • Harada J, Foley M, Moskowitz MA, Waeber C (2004) J Neurochem 88: 1026-1039.
  • Kerr JFR, Wyllie AH, Currie AR (1972) Br J Cancer 26: 239-257.
  • Lockman K, Hinson JS, Medlin MD, Morris D, Taylor JM, Mack CP (2004) J Biol Chem 279: 42422-42430.
  • Mengubas K, Riordan FA, Bravery CA, Lewin J, Owens DL, Mehta AB, Hoffbrand AV, Wickremasinghe RG (1999) Oncogene 18: 2499-2506.
  • Miller F, Kaplan DR (2001) Cell Mol Life Sci 58: 1045-1053.
  • Pascual M, Valles SL, Renau-Piqueras J, Guerri C (2003) J Neurochem 87: 1535-1545.
  • Pebay A, Toutant M, Premont J, Calvo CF, Venance L, Cordier J, Glowinski J, Tence M (2001) Eur J Neurosci 13: 2067-2076.
  • Spiegel S, Cuvillier O, Edsall LC, Kohama T, Menzeleev R, Olah Z, Olivera A, Pirianov G, Thomas DM, Tu Z, Van Brocklyn JR, Wang F (1998) Ann N Y Acad Sci 845: 11-18.
  • Stoica BA, Movsesyan VA, Lea PM, Faden AI (2003) Mol Cell Neurosci 22: 365-382.
  • Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H, Hakomori S, Igarashi Y (1996) Int J Cancer 66: 358-366.
  • Van Brocklyn JR, Tu Z, Edsall LC, Schmidt RR, Spiegel S (1999) J Biol Chem 274: 4626-4632.
  • Wajant H, Pfizenmaier K, Scheurich P (2003) Cytokine Growth Factor Rev 14: 53-66.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv52p927kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.